SERB
Location
ILE DE FRANCE
Founded
1951-07-25
Website
Risk Signals
32 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Pharmaceutical Preparations), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about SERB
Live alerts from global media, monitored by Business Radar
2024-10-21 (globenewswire.com)
SERB Pharmaceuticals expands leading emergency care portfolio with acquisition of Aurlumyn™ (iloprost IV) for severe frostbite
Philadelphia, PA, Oct. 21, 2024 (GLOBE NEWSWIRE) -- SERB Pharmaceuticals, a global specialty pharmaceutical company, announced today the acquisition of...
Read more
2024-07-31 (globenewswire.com)
SERB Pharmaceuticals strengthens leadership in medical countermeasures with the global acquisition of RSDL® (Reactive Skin Decontamination Lotion) kit for $75 million
Philadelphia, PA, July 31, 2024 (GLOBE NEWSWIRE) -- SERB Pharmaceuticals, a global specialty pharmaceutical company, announced today the acquisition of...
Read more
2023-07-13 (globenewswire.com)
SERB Pharmaceuticals acquires Vistogard® and Xuriden® from Wellstat Therapeutics
West Conshohocken, PA, July 13, 2023 (GLOBE NEWSWIRE) -- SERB Pharmaceuticals, a global specialty pharmaceutical company, announced today that it has...
Read more
2021-03-02 (prnewswire.com)
SERB completes acquisition of BTG Specialty Pharmaceuticals to create a global leader in critical care medicines
/PRNewswire/ -- SERB Specialty Pharmaceuticals ("SERB"), a leading European specialty pharmaceutical group focused on prescription medicines that address rare...
Read more
2020-12-01 (medtechdive.com)
Zimmer puts up $250M in surgical device deal, Boston Scientific nets $800M in BTG pharma sell-off |
The pandemic hasn't stopped M&A in the medtech industry, with Zimmer Biomet adding to its sternal closure device lineup via A&E Medical and Boston Scientific streamlining business with a sale to specialty pharma group SERB.
Read more
2020-12-01 (penews.com)
Charterhouse-backed SERB buys BTG specialty pharma unit for $800m
The sale is expected to complete in the first half of 2021
Read more
(pharmaceutical-technology.com)
SERB Pharmaceuticals buys US rights for bentracimab from SFJ
Speciality pharmaceutical company SERB Pharmaceuticals has acquired exclusive US rights for bentracimab from SFJ Pharmaceuticals.
Read more